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Abstract
Actinobaculum schaalii is a new species that has so far been isolated from human blood, urine and pus. Its importance has probably been
underestimated and other Actinobaculum spp. may also have been underdiagnosed. This retrospective study comprises all known cases
of A. schaalii infections identiﬁed since 2004 in the canton of Neuchaˆtel (170 000 inhabitants), Switzerland. Strains were cultivated and
isolated in the bacteriology laboratory using its routine procedure. Identiﬁcation included a Rapid ID 32 A strip (bioMe´rieux) and 16S
rRNA gene sequencing. Twenty-one positive samples were found in 19 patients (11 male, 8 female) of all ages (range 16–91 years): 10
from urine (50%), six from blood (30%), one from both blood and urine (5%), and three from pus (15%). Thirteen out of 17 (76%)
cases with either blood or urine specimens had underlying genitourinary tract pathologies. When urine cultures were positive for
A. schaalii, leucocytes were found in all samples (10/10, 100%) but all nitrite tests were negative (10/10, 100%). The onset of appropriate
treatment was delayed due to the diminished sensitivity of A. schaalii to the antibiotics commonly used for UTIs (i.e. ciproﬂoxacin and
trimethoprim/sulfamethoxazole) and to the delay in microbiological diagnosis. A. schaalii should speciﬁcally be searched in all cases of
leukocyturia with a negative nitrite test but with Gram-positive rods in the Gram stain, in patients with underlying genitourinary tract
pathology, instead of dismissing these ﬁndings as clinically irrelevant colonization by coryneform bacteria. This infection may be much
more common than previously thought.
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Background
In 1997, Lawson et al. [1] proposed reclassifying Actinomyces
suis in a new genus: Actinobaculum. They classiﬁed the human
strains in a new species called Actinobaculum schaalii. In 2003,
two new species were added: Actinobaculum urinale, isolated
from the urine of two patients with urinary tract infections
(UTI’s), and Actinobaculum massiliae, isolated from the urine
of a patient with UTI and from the pus of a superﬁcial skin
infection [2,3]. The genus Actinobaculum suis is well known in
veterinary medicine and causes UTI and metritis in sows.
Actinobaculum spp. are Gram-positive, straight to slightly
curved, non-motile, facultatively anaerobic coccoid rods.
They grow well after 48 h in an anaerobic atmosphere at
37C, forming circular, grey colonies of 0.2–1 mm in diame-
ter. They are catalase, urease and oxidase negative, and have
been isolated from urine, blood and pus, and predominantly
cause UTI but also bacteraemia, osteomyelitis, abscesses and
superﬁcial skin infections [4–8]. Elderly people with underly-
ing genitourinary tract pathologies seem to be the most
affected.
Actinobaculum spp. infections may be much more common
than previously thought, as some microbiological laboratories
do not perform urine Gram stains and miss the direct detec-
tion of the bacteria [3,8]. Moreover, the presence of Gram-
positive rods in the urine is often interpreted as colonization
with corynebacteria or lactobacilli [5]. It grows slowly, and
thus might be overgrown by other pathogens or commensals
that are often found concomitantly [9].
Since 2004, we have started to look actively for A. schaalii.
When cultures of patients with UTIs and Gram-positive rods
in the urine showed minute colonies on blood agar plates, pro-
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longed incubation was undertaken, as well as identiﬁcation
using Rapid ID 32 A strips and 16S rRNA gene sequencing.
The aim of this study was to investigate all patients suffer-
ing from an infection caused by A. schaalii and to deﬁne their
demographic and clinical characteristics while trying to deter-
mine some key elements that would make clinicians think of
A. schaalii infection and initiate an active search for it.
Patients and Methods
This is a retrospective study including all known cases of
Actinobaculum schaalii infections since 2004 in the canton of
Neuchaˆtel (170 000 inhabitants), Switzerland. ADMED
Microbiologie, the reference laboratory for this study, per-
forms clinical microbiology testing for the different hospitals
of the region as well as for some local general practitioners.
Native urine samples were cultured on 5% Columbia human
blood agar plates (bioMe´rieux, Marcy L’Etoile, France) incu-
bated with 5% CO2 at 35C overnight as a routine procedure.
Blood was inoculated in two pairs of Bactec (Becton Dickinson,
Franklin Lakes, NJ, USA) blood culture bottles including aerobic
and anaerobic conditions. Other samples were cultured on
agar plates in atmospheric conditions as recommended in
standard laboratory practice manuals. In the case of insufﬁ-
cient growth, incubation was extended to 48 h.
Observation of tiny non-haemolytic colonies of Gram-
positive, catalase-negative bacilli (GPB) was carried out if the
presence of A. schaalii was suspected. Isolation and culture
were performed in aerobic or anaerobic conditions. Identiﬁ-
cation was performed using Rapid ID 32A strips (bio-
Me´rieux) according to the manufacturer’s instructions. To
determine a screening strategy some individual biochemical
tests were added using DIATABS (Rosco Diagnostica, Taast-
rup, Denmark): pyrrolidonyl aminopeptidase (PYR), urease
(URE), nitrate reduction (NIT) and esculine hydrolysis (ESC).
Molecular identiﬁcation was based on 16S rRNA gene
sequencing [10–12]. Results on approximately 400–450 bp
were compared using the Basic Local Alignment Search Tool
(BLAST) of the National Center for Biotechnology Informa-
tion (NCBI) web site. We considered >99% identiﬁcation
rate an acceptable criteria as long as no other bacterial gen-
der followed the closer match.
All A. schaalii isolates were tested for antibiotic resistance
by E-test MIC determination (bioMe´rieux). An inoculum sus-
pension of MacFarland 1 in 0.9% NaCl was spread on Schaedler
agar (Oxoid) supplemented with Hemin and Vitamin K1, and
incubated in anaerobic conditions at 35C for 48–72 h.
The charts of all patients from whom A. schaalii was iso-
lated were collected. Their demographic data (age, sex and
comorbidities, with special attention to genitourinary tract
pathologies), clinical and microbiological characteristics, such
as sample origin (urine, blood or pus), and their medical his-
tories were noted. Patients were treated as outpatients or in
the hospital wards. C-reactive protein (CRP), leukocyte
count, creatinine, urinary test strips and urine sediment were
all included in the study. Patients’ outcomes were analysed
according to the antibiotic treatment, duration of the treat-
ment, and also in relation to the delay between presentation
and start of treatment.
Results
Between January 2004 and June 2009 we identiﬁed 21
A. schaalii-positive samples in 19 patients [11 male (58%),
eight female (42%)], one of them being positive for two con-
secutive years and one having simultaneously positive sam-
ples from both urine and blood. Specimens positive for
A. schaalii were found in urine, 10/20 (50%), blood, 6/20
(30%), urine and blood, 1/20 (5%), and pus, 3/20 (15%).
According to the clinical presentation, 9/20 (45%) had cys-
titis, 2/20 (10%) pyelonephritis, 2/20 (10%) skin abscesses
(located either on the breast or in the inguinal fold), 6/20
(35%) suffered from bacteraemia, and 1/20 (5%) had urosep-
sis. Sixteen out of 20 (80%) were symptomatic of their infec-
tion, showing either urinary symptoms such as alguria,
dysuria, suprapubic and kidney pain, or more general symp-
toms of infection such as fever, tachycardia and hypotension.
Eighteen out of twenty-one (86%) specimens were mono-
bacterial. Only one blood culture and the two skin abscesses
were polybacterial. We found six cases with bacteraemia
only. Four out of six (66%) had urine cultures, none of which
was positive for A. schaalii, but 3/4 (75%) showed coryneform
Gram-positive rods in the Gram stain, suggesting that urine
might be the source of infection.
The patients’ ages ranged from 16 to 91 (mean 65) years,
with 60% being over 70 years old. They had different comor-
bidities (Table 1), and 14/17 (82%) cases with positive urine
or blood specimens had an underlying genitourinary tract
pathology. Ten out of 20 (50%) were outpatients, of whom
nine (90%) had a benign infection (cystitis or skin abscess).
The other ten patients were hospitalized, of whom eight
(80%) had a major infection (pyelonephritis, bacteraemia).
One patient, suffering from an adenocarcinoma of the endo-
metrium with multiple metastases (liver and pelvis), died.
Identiﬁcation by Rapid ID 32A strips yielded mainly the
numerical codes 0400077705 and 0404077705, with some
individual variations, all corresponding to the identiﬁcation of
Actinomyces meyeri, with a probability >90% and a T value
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(distance to type strain) varying from 0.4 to 0.9. Table 2
shows the most discriminant tests for phenotypical identiﬁca-
tion. Bacterial identiﬁcation using 16S rRNA gene partial
sequencing (400–450 bp) yielded good identiﬁcation rates
(>99.5%) in 17/20 strains (85%, Table 3). Three strains show-
ing results of 97% and 98% homology could be possibly con-
sidered as low level identiﬁcation. However, the closer
match with a totally unrelated genre (Myceligenerans xiligou-
ense) did not show an identiﬁcation rate higher than 92%.
Moreover, morphological, physiological and phenotypical
traits enabled us to accept them as A. schaalii strains. One
strain showing identical phenotypical characteristics could
not be sequenced.
When urine cultures were positive for A. schaalii, leuko-
cyturia and Gram-positive rods were found in all samples
(10/10, 100%), but nitrite tests were always negative. Patients
having a major infection showed high levels of CRP (mean
138 mg/l, range 93–191) and leukocytosis (mean 11.6 G/l,
range 7.5–16.2). Renal function was mainly impaired, with a
mean creatinine of 175.3 lmol/L (range 71–382) and a mean
MDRD of 31 ml/min/1.73 m2 (range 11–102). Unfortunately,
we did not have enough data to show a real trend for a spe-
ciﬁc value.
There are no recognized MIC interpretive standards for
this bacterial genus. Nevertheless, most of the strains (15/20,
75%) showed high MIC levels to ciproﬂoxacin (>32 mg/L),
and the remaining ﬁve strains (25%) showed an MIC value
between 4 and 12 mg/L (one MIC could not be obtained).
Eight out of 20 strains (40%) presented high MIC levels to
trimethoprim/sulfamethoxazole, with values >32 mg/L, and all
20 strains (100%) showed low MIC level to beta-lactams
(£0.19 for penicillin, Table 4). As most antibiotics empirically
prescribed for urinary infection (mainly ﬂuoroquinolones or
trimethoprim/sulfamethoxazole) are not effective against
A. schaalii, the appropriate onset of treatment was delayed
by an average of 2.8 days (range 0–13). This included cases
treated with antibiotics ineffective against A. schaalii, as
shown by susceptibility testing.
Discussion
To our knowledge, this is the largest clinically documented
series of A. schaalii infections published to date. Different
TABLE 1. Demographic, clinical and microbiological charac-
teristics of 19a patients suffering from an Actinobaculum
schaalii infection
Mean age 65 years (16–91)
Sex ratio 8F (42%)/11M (52%)
Hospitalization 10/20 (50%)
Specimen with Actinobaculum spp.: 21
Blood 6 (30%)
Blood and urine 1 (5%)
Urine 10 (50%)
Pus 3 (15%)
Genitourinary tract infectionsb 11/20 (55%)
Underlying genitourinary tract pathologyc 13/17 (76%)
Urine (gram, stix and sediment)
Gram-positive rodsd 10/10 (100%)
Nitrite test 0/10 (0%)
Leucocytes 10/10 (100%)
Comorbidities
Hypertension 9/19 (47%)
Cancer 6/19 (32%)
Chronic kidney failure 5/19 (26%)
Ischaemic heart disease 5/19 (26%)
Hypercholesterolaemia 5/19 (26%)
Diabetes 3/19 (16%)
Kidney transplantation 2/19 (11%)
Mean duration to diagnosis 8.4 days (2–25)
Mean duration to appropriate treatment 2.8 days (0–13)
aOne patient positive for two consecutive years and one simultaneously positive
for both urine and blood.
b9 cystitis, 2 pyelonephritis.
cIn blood and urine specimens (some patients had more than one): benign pros-
tatic hyperplasia (5), bladder carcinoma (3), kidney transplantation (2), urethral
stenosis (2), hypospadias, bladder kidney reﬂux, kidney atrophy, prostate carci-
noma, neurological bladder, hydronephrosis.
d5/10 were coryneform.
TABLE 2. Characterization of tested Actinobaculum schaalii
strains (n = 21) vs. given result from Actinomyces meyeri by
Rapid ID 32A
Characteristics A.s. % A.m. %
Nitrate reduction 0 15
Indole 0 0
Pyrrolidonyl aminopeptidase 90 0
Alkaline phosphatase 0 7
Urease activity 0 0
Alpha-Glucosidase 100 100
Beta-Glucuronidase 0 7
Alpha-Galactosidase 0 0
Beta-Galactosidase 0 92
N-acetyl-beta-glucosaminidase 0 50
Glutamyl glutamic acid arylamidase 0 46
TABLE 3. BLAST best match results for Actinobaculum
schaalii strains (n = 21)
Case Sequence length Identiﬁcation rate Genbank access
1a 456 100 FJ711184.1
1b 456 100 FJ711184.1
2 456 99 FJ711184.1
3 466 100 FJ711190.1
4 476 99.8 AF487680.1
5 468 98 FJ711184.1
6a 397 100 FJ711193.1
6b 397 100 FJ711193.1
7 476 99.8 AF487680.1
8 456 100 FJ711184.1
9 466 100 AY957507.2
10 463 100 AY957507.2
11 397 97 FJ960443.1
12 454 100 FJ711184.1
13 466 100 AY957507.2
14 456 100 FJ711184.1
15 476 99.8 AF487680.1
16 466 100 AY957507.2
17 466 100 AY957507.2
18 477 98 EF151128.1
19 ND ND ND
ND, not determined (strain lost).
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studies showed that A. schaalii predominantly causes UTI
[4,5,7]. The spectrum of infection ranges from benign cystitis
to severe pyelonephritis with bacteraemia, indicating that this
pathogen may become invasive [3,5]. Cases of osteomyelitis,
intradural abscess and superﬁcial skin infections have also
been described [4,5]. In our series, two patients had skin
abscesses caused by A. schaalii (in the breast and inguinal
fold). To our knowledge, these are the ﬁrst descriptions of
skin abscesses due to A. schaalii.
It seems that elderly people, especially patients older than
70 years, are the population most at risk [3,5]. In our series,
the sex ratio was in favour of male patients, which could be
explained by the fact that these often suffered from benign
prostatic hyperplasia, 5/19 (26%), which seems to be a pre-
disposition for subsequent infection. Most of the patients had
comorbidities such as hypertension, chronic renal failure, dia-
betes and heart disease, but 13/17 (82%) with either positive
urine or blood specimens had an underlying genitourinary
tract pathology, which seems to be a major risk factor
[4,5,7,8]. Two of our patients had a kidney transplant, being
the ﬁrst cases described to date. A prospective study on
A. schaalii infections after kidney transplant should be per-
formed because we do not yet know if immunosuppression
is a risk factor.
All described cases in the literature were hospitalized
patients. As our laboratory also receives samples from gen-
eral practitioners, some infected outpatients could also be
followed.
In positive urine cultures, leukocyturia and Gram-positive
rods were always found, but nitrite tests were always nega-
tive. As far as other test results are concerned, we could
not ﬁnd any speciﬁc element other than those usually
encountered in infections (leukocytosis and elevated CRP).
These results show that A. schaalii infection is not only of
intrahospital concern but also a widespread phenomenon
because several cases were diagnosed as outpatients.
TABLE 4. Treatment and antibiotic MICs (mg/L) of 21 strains of Actinobaculum schaalii
Case Treatment P AMC CRO CIP SXT CC
1a Ceftriaxone 10 days 0.03 0.19 0.06 >32 6 0.02
Amoxicillin/clavulanic acid 30 days
1ba Amoxicillin/clavulanic acid 11 days 0.02 0.09 0.09 >32 >32 0.02
2 Ceftriaxone 3 days 0.02 0.09 0.05 >32 >32 0.02
Clarithromycine 3 days
3 Ciproﬂoxacin 1 day 0.01 0.19 0.00 >32 >32 0.02
4 Ceftriaxone 7 days 0.01 0.13 0.09 >32 0.75 0.02
5 Clarithromycine 1 day NA NA NA NA NA NA
Ceftriaxone 2 days
Cefuroxime 10 days
6ab Tazobactam/piperacillin 2 days 0.03 0.19 0.09 6 0.25 0.03
Penicillin 2 days
Amoxicillin 14 days
6bb Tazobactam/piperacillin 2 days 0.05 0.13 0.09 4 0.25 0.05
Penicillin 2 days
Amoxicillin 14 days
7 Ciproﬂoxacin 10 days 0.02 0.19 0.09 >32 0.5 0.02
8 Ceftriaxone 5 days 0.02 0.09 0.06 6 1.5 0.02
Ciproﬂoxacin 17 days
Linezolide 16 days
9 Cefepim 6 weeks 0.02 0.19 0.06 >32 0.19 0.03
Metronidazol 1
Clarithromycinec
10 None 0.01 0.19 0.02 4 >32 0.02
11 Trimethoprim/sulfamethoxazole 3 days 0.09 0.13 0.13 >32 0.19 0.03
Ciproﬂoxacin 4 days
Ceftriaxone 3 days
Cefuroxime 7 days
12 Ciproﬂoxacin 4 days 0.02 0.09 0.13 >32 >32 0.03
13 None 0.02 0.19 0.09 >32 >32 0.02
14 Flucloxacillin 6 days 0.03 0.09 0.09 >32 0.38
Amoxicillin/clavulanic acid 7 days
15 Ciproﬂoxacin 9 days 0.03 0.19 0.09 >32 >32 0.02
Amoxicillin 10 days
16 Amoxicillin/clavulanic acid 7 days 0.02 0.13 0.05 >32 0.09 0.02
17 NA 0.03 0.38 0.09 >32 0.05 0.02
18 NA 0.19 0.09 0.19 12 0.38 0.02
19 Amoxicillin/clavulanic acidc 0.13 0.13 0.38 >32 >32 6
Metranidazol 3 days
Azithromycin 1 day
Trimethoprim/sulfamethoxazole 10 days
P, penicillin; AMC, amoxicillin/clavulanic acid; CRO, ceftriaxone; CIP, ciproﬂoxacin; SXT, trimethoprim/sulfamethoxazole; CC, clindamycin.
aSame patient as No. 1, 1 year later.
bBlood and urine strains of the same patient.
cUndetermined duration.
dMIC given in trimethoprim concentration.
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As published previously, A. schaalii shows diminished sus-
ceptibility to the commonly used antibiotics in UTI (particu-
larly ciproﬂoxacin), but is highly susceptible to beta-lactams
[4,7]. The open question is the duration of treatment.
Because of the delay in microbiological diagnosis, most of
the patients received different antibiotics for longer periods,
which makes it difﬁcult to recommend optimal treatment
and its duration. Interestingly, one patient presenting with a
urosepsis recovered after being treated by ceftriaxone for
10 days and amoxicillin/clavulanic acid for 30 days. He was
readmitted 1 year later with bacteraemia caused by the same
microorganism. This raises questions about the length of
treatment and whether a chronic carrier state is possible.
Attempts to isolate A. schaalii were not done systemati-
cally. Therefore, we have no information as to the preva-
lence of this infection. A prospective study would be
necessary to answer this question.
As shown in Table 2, selected phenotypical characteristics
were useful in the identiﬁcation of our A. schaalii strains. To
exclude possible Actinomyces meyeri, the infrequently positive
(15%) reduction of nitrate could not be used for the differ-
entiation from other Actinomyces spp. The selected tests
included the absence of beta-galactosidase and the presence
of PYR in A. schaalii strains. Bank et al., using gyrase B gene
ampliﬁcation by quantitative real-time PCR, showed that
A. schaalii was often associated with E. coli or another en-
terobacteria, making it impossible to isolate A. schaalii with-
out the use of selective blood plates supplemented with
colistin and nalidixic acid antibiotics [9]. None of the strains
showed beta-haemolysis but some presented a partial haem-
olysis on human and sheep blood Columbia agar plates. Sus-
picious colonies with haemolysis were identiﬁed as
Gardnerella vaginalis or Arcanobacterium spp. strains, showing
clearly that this marker is associated with a low predictive
value.
In conclusion, A. schaalii is most likely a common cause of
UTI, especially among elderly male patients. The spectrum
extends from benign cystitis to pyelonephritis with bactera-
emia, indicating that the pathogen can be invasive. In cases
involving leukocyturia with a negative nitrite test but Gram-
positive rods in the Gram stain and an underlying genitouri-
nary tract pathology, A. schaalii should speciﬁcally be included
in the microbiological search of pathogens instead of dismiss-
ing its presence as clinically irrelevant colonization by co-
rynebacteria or Lactobacillus spp. Microbiology laboratory
management should include a native urine Gram stain and
selective blood agar plates and incubation should be
extended to 2–3 days. A. schaalii seems to be susceptible to
beta-lactams but shows diminished susceptbility to commonly
used antibiotics in UTIs like ciproﬂoxacin or trimethoprim/
sulfamethoxazole. A prospective study on A. schaalii infec-
tions should be performed to conﬁrm these results and
determine the appropriate treatment and its duration.
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